Hemangeol

Thyroid Crisis, Atrial Fibrillation, Migraine + 23 more
Treatment
5 FDA approvals
20 Active Studies for Hemangeol

What is Hemangeol

PropranololThe Generic name of this drug
Treatment SummaryPropranolol is a medication used to treat high blood pressure and other conditions. It is a mixture of two different chemical compounds, with one of them being about 100 times more powerful in binding to beta adrenergic receptors. Propranolol was first approved by the FDA in 1967.
Inderalis the brand name
image of different drug pills on a surface
Hemangeol Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Inderal
Propranolol
1967
471

Approved as Treatment by the FDA

Propranolol, also known as Inderal, is approved by the FDA for 5 uses including Obstructive Hypertrophic Cardiomyopathy and Tremor, Essential .
Obstructive Hypertrophic Cardiomyopathy
Tremor, Essential
Helps manage Tremor, Essential
Essential Tremor
Helps manage Tremor, Essential
Cardiomyopathy, Hypertrophic
Hypertensive disease
Used to treat High Blood Pressure (Hypertension) in combination with Hydrochlorothiazide

Effectiveness

How Hemangeol Affects PatientsPropranolol is a drug used to treat high blood pressure. It lasts for a long time, so it is usually taken once or twice per day, depending on the patient's needs. If the patient suddenly stops taking propranolol, they may experience chest pain and heart attacks.
How Hemangeol works in the bodyPropranolol works by blocking the effect of beta-adrenergic receptors. This causes the blood vessels to constrict, reduces the growth of new blood vessels, and encourages the death of endothelial cells. It also reduces the activity of the renin-angiotensin-aldosterone system.

When to interrupt dosage

The measure of Hemangeol is contingent upon the diagnosed ailment, such as Catecholamines, Hypertensive disease and Hemangiomas. The quantity of dosage is contingent upon the mode of delivery (e.g. Solution - Oral or Capsule, extended release - Oral) featured in the table below.
Condition
Dosage
Administration
Adrenergic Alpha-Antagonists
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Heart Attack
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Tachyarrhythmia caused by Digitalis intoxication
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Psychomotor Agitation
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Tremor
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Thyrotoxicosis
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Chest Pain
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Supraventricular Arrhythmias
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Hemangioma
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Cardiomyopathy, Hypertrophic
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Proliferating Infantile Hemangioma
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Hypertensive disease
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Performance Anxiety
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Pheochromocytoma
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Ventricular Tachycardia
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Migraine
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Gastroesophageal variceal hemorrhage prophylaxis
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Catecholamines
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Migraine Disorders
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral
Atrial Fibrillation
, 1.0 mg/mL, 60.0 mg, 80.0 mg, 120.0 mg, 160.0 mg, 40.0 mg, 10.0 mg, 20.0 mg, 50.0 mg, 0.1 mg, 4.28 mg/mL, 4.0 mg/mg, 2.0 mg/mg, 20.0 mg/mL, 40.0 mg/mL, 3.75 mg/mL
, Intravenous, Injection, Injection - Intravenous, Capsule, extended release, Capsule, extended release - Oral, Oral, Tablet, Tablet - Oral, Injection, solution, Injection, solution - Intravenous, Solution, Solution - Oral, Solution - Intravenous, Liquid, Liquid - Intravenous, Capsule, gelatin coated, Capsule, gelatin coated - Oral

Warnings

Hemangeol has fifteen contraindications, so it should be avoided in cases where any of the conditions in the table below are present.Hemangeol Contraindications
Condition
Risk Level
Notes
Heart Decompensation
Do Not Combine
Bronchial Spasm
Do Not Combine
Asthma
Do Not Combine
Infants Weighing <2kg
Do Not Combine
Low Blood Pressure
Do Not Combine
Sick Sinus Syndrome
Do Not Combine
Asthma
Do Not Combine
Pheochromocytoma
Do Not Combine
Atrioventricular Block
Do Not Combine
Slow Heart Rate
Do Not Combine
Shock, Cardiogenic
Do Not Combine
Heart Decompensation
Do Not Combine
Prematurity
Do Not Combine
Sinus Bradycardia
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Propranolol may interact with Pulse Frequency
There are 20 known major drug interactions with Hemangeol.
Common Hemangeol Drug Interactions
Drug Name
Risk Level
Description
4-Bromo-2,5-dimethoxyphenethylamine
Major
The therapeutic efficacy of 4-Bromo-2,5-dimethoxyphenethylamine can be decreased when used in combination with Propranolol.
4-Methoxyamphetamine
Major
The therapeutic efficacy of 4-Methoxyamphetamine can be decreased when used in combination with Propranolol.
Abediterol
Major
Propranolol may decrease the bronchodilatory activities of Abediterol.
Adrafinil
Major
The therapeutic efficacy of Adrafinil can be decreased when used in combination with Propranolol.
Agrostis gigantea pollen
Major
The risk of a hypersensitivity reaction to Agrostis gigantea pollen is increased when it is combined with Propranolol.
Hemangeol Toxicity & Overdose RiskSymptoms of propranolol overdose include low blood pressure, seizures due to low blood sugar, restlessness, and lack of sleep. Asthma sufferers may experience difficulty breathing. If someone overdoses on propranolol, monitor their vital signs, mental status, and blood sugar. Treat low blood pressure with fluids, slow heart rate with atropine and isoproterenol or aminophylline for difficulty breathing. If fluids don't help, try giving glucagon intravenously, followed by catecholamines. Dialysis will not help since propranolol binds to proteins in the blood.
image of a doctor in a lab doing drug, clinical research

Hemangeol Novel Uses: Which Conditions Have a Clinical Trial Featuring Hemangeol?

Currently, 249 active studies are assessing the potential of Hemangeol to ameliorate Migraine, Catecholamines and Hypertensive diseases.
Condition
Clinical Trials
Trial Phases
Atrial Fibrillation
94 Actively Recruiting
Not Applicable, Phase 2, Phase 4, Phase 1, Phase 3, Early Phase 1
Heart Attack
23 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Early Phase 1, Phase 3
Coronary Artery Disease
1 Actively Recruiting
Not Applicable
Chest Pain
2 Actively Recruiting
Not Applicable, Phase 2, Phase 3
Adrenergic Alpha-Antagonists
0 Actively Recruiting
Migraine
51 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 3, Phase 2, Early Phase 1
Hemangioma
0 Actively Recruiting
Gastroesophageal variceal hemorrhage prophylaxis
0 Actively Recruiting
Migraine Disorders
1 Actively Recruiting
Phase 3
Catecholamines
0 Actively Recruiting
Thyroid Crisis
0 Actively Recruiting
Hypertensive disease
27 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Pheochromocytoma
0 Actively Recruiting
Thyrotoxicosis
0 Actively Recruiting
Cardiovascular Mortality
0 Actively Recruiting
Myocardial Infarction
0 Actively Recruiting
Tremor
0 Actively Recruiting
Cardiomyopathy, Hypertrophic
0 Actively Recruiting
Proliferating Infantile Hemangioma
0 Actively Recruiting
Psychomotor Agitation
0 Actively Recruiting

Hemangeol Reviews: What are patients saying about Hemangeol?

4Patient Review
6/17/2014
Hemangeol for A Feeling of Restlessness with Inability to Sit Still
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about hemangeol

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is HEMANGEOL a beta blocker?

"Hemangeol belongs to a class of drugs that help to regulate heart rate and treat conditions like angina and migraines."

Answered by AI

Is Hemangeol the same as propranolol?

"The medicine propranolol is not able to be removed by dialysis. HEMANGEOL is an oral solution of propranolol that does not contain alcohol, parabens, or sugar. Each mL of HEMANGEOL contains 4.28 mg of propranolol hydrochloride, USP equivalent to 3.75 mg of propranolol."

Answered by AI

How long does it take for Hemangeol to work?

"8 out of 10 babies in this study improved after 5 weeks of using HEMANGEOL with 60% of them seeing complete or nearly complete resolution of their hemangiomas by 6 months."

Answered by AI

What is Hemangeol used for?

"HEMANGEOL is a medication that is used to treat a type of birthmark called an infantile hemangioma. This condition requires treatment with a medication that enters the bloodstream and circulates throughout the body."

Answered by AI

Clinical Trials for Hemangeol

Image of Inova Alexandria Hospital in Alexandria, United States.

Heparin Dosing for Blood Clots and Heart Conditions

18+
All Sexes
Alexandria, VA
The goal of this clinical trial study is to test whether a mathematical calculation, using the patient's gender, weight and kidney function, can better predict a patient's heparin goal dose than a flat number of units per patient weight can. Participants will have the first dose of heparin infusion calculated, after which if adjustments are needed, the Hospital's prebuilt table for results driven dosing for this purpose is used. The researchers will compare the time it takes for the participants to get to the desired goal using the patient's information for calculation versus patients in the past who received the medication using the flat rate. The hypothesis is that the patients with enhanced personal data, gender, weight and kidney function, included for the initial dose, will get to their goal lab value sooner and with less chance of delay or overshooting the goal. A quicker time to goal lab value is beneficial to patients in many ways, including earlier treatment of the clot or coronary issue that the patient is experiencing.
Phase 4
Waitlist Available
Inova Alexandria Hospital
Image of U Health in Miami, United States.

Cuffless PPG Monitor for High Blood Pressure

18+
All Sexes
Miami, FL
This study aims to validate the accuracy and reliability of blood pressure (BP) estimates obtained over 24 hours using a PPG-based chest-patch device compared to the gold standard ambulatory blood pressure monitoring (ABPM) method using an upper arm cuff-based oscillometric BP device, in both hypertensive and normotensive individuals referred by their provider to undergo a 24-hours ABPM for clinical indication. The Awake/Asleep test, which is the primary test recommended for automated wearable cuffless BP devices that are cuff-calibrated (based on the 2023 European Society of Hypertension (ESH) recommendations for the validation of cuffless blood pressure measuring devices), will be conducted in this study. The secondary aim of the study is to assess the feasibility and convenience of the PPG-based device.
Waitlist Available
Has No Placebo
U Health (+1 Sites)Ziad Zoghby, M.D., M.B.A.Biobeat Technologies Ltd.
Have you considered Hemangeol clinical trials? We made a collection of clinical trials featuring Hemangeol, we think they might fit your search criteria.Go to Trials
Image of Johns Hopkins Medicine in Baltimore, United States.

Embolization for Migraine

18 - 80
All Sexes
Baltimore, MD
This study is to test the safety and feasibility of a procedure called embolization of the middle meningeal arteries (MMA), using a product called Onyx. Embolization creates a plug in the arteries. MMA embolization with Onyx is not approved for use in patients with migraines, but is currently used in patients with subdural hematomas. The FDA is allowing the use of Onyx in this study. It is thought that by using Onyx to block the middle meningeal arteries, the amount of migraine-causing substances which are released into the brain's bloodstream will be reduced. The company that manufactures Onyx, Medtronic, is providing the supplies for this study. Participants will be in the study for about 8 months after enrolling, including 6 months of follow up after the procedure. The participants will be asked to complete a daily headache diary and continue the participant's regular migraine medications. Participants will also have several clinic visits and be asked to provide blood samples for research.
Waitlist Available
Has No Placebo
Johns Hopkins MedicineRisheng Xu, MD, PhDMedtronic
Have you considered Hemangeol clinical trials? We made a collection of clinical trials featuring Hemangeol, we think they might fit your search criteria.Go to Trials
Image of St Boniface Hospital in Winnipeg, Canada.

Remote Home Monitoring for Heart Attack

18+
All Sexes
Winnipeg, Canada
Heart attacks are one of the top causes of death in Canada, with over 2,100 cases treated each year in Manitoba. Even though hospital care has improved, the period after going home is still risky. Many patients feel anxious and unsure about their recovery, and without enough support, they often end up back in the emergency department (ED). This is an even bigger challenge for people in rural areas, where getting follow-up care can be much harder. Filling these gaps is important to help patients get better and to reduce stress on the healthcare system. In a previous study, the investigators found that extra support made a big difference: only 8% of participants using a digital health tool returned to the ED within 30 days, compared to 22% of participants without it. Now, the investigators want to expand this study across Manitoba to see if digital health tools can help more people recover safely at home. The investigators will compare two types of follow-up care: education only versus education with extra support (like symptom tracking and virtual appointments). The investigators will look at how this affects hospital visits, mental well-being, and healthcare costs. The goal is to create a better support system for people after a heart attack, leading to healthier recoveries, less strain on hospitals, and better care for Manitobans - no matter where they live.
Waitlist Available
Has No Placebo
St Boniface Hospital
Image of University of the Fraser Valley in Chilliwack, Canada.

Mind-Body App + Movement Program for Chronic Pain

19 - 75
All Sexes
Chilliwack, Canada
The investigators are evaluating the effects of a mind-body mobile application, in combination with a guided movement program, on the experience of chronic pain. Participants meeting the criteria for chronic/persistent pain (confirmed via self-report) will complete an online baseline questionnaire. Eligible participants will take part in an intervention that involves use of a 6-week free trial of a mind-body focused mobile application in combination with virtual asynchronous audio-guided somatic education sessions (gentle movement). External data from a usual care control arm and a mobile-app-only arm from a previous study by the same research team, National Clinical Trials (NCT) registry number NCT05090683, will be used for comparison with the current combined intervention. All participants will complete online surveys at the start of the study and after 6 weeks to measure pain intensity and interference (primary outcomes), mental health outcomes (depression, anxiety, stress), pain-related thoughts (pain catastrophizing), quality of life, and fear of movement (secondary outcomes). From weeks 2 to 6, participants will fill out weekly surveys to track how often they engage with each: the somatic education (gentle movement) program and the mobile app. Participants will also complete a follow-up survey at 12 weeks (6 weeks post-intervention conclusion).
Waitlist Available
Has No Placebo
University of the Fraser ValleyCynthia J Thomson, PhD
Have you considered Hemangeol clinical trials? We made a collection of clinical trials featuring Hemangeol, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security